|
Gene: PPIL1 |
Gene summary for PPIL1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PPIL1 | Gene ID | 51645 |
Gene name | peptidylprolyl isomerase like 1 | |
Gene Alias | CGI-124 | |
Cytomap | 6p21.2 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A024RCX8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51645 | PPIL1 | P126T-E | Human | Esophagus | ESCC | 4.73e-06 | 5.36e-01 | 0.1125 |
51645 | PPIL1 | P127T-E | Human | Esophagus | ESCC | 3.36e-08 | 1.62e-01 | 0.0826 |
51645 | PPIL1 | P128T-E | Human | Esophagus | ESCC | 1.35e-36 | 9.25e-01 | 0.1241 |
51645 | PPIL1 | P130T-E | Human | Esophagus | ESCC | 3.32e-68 | 1.62e+00 | 0.1676 |
51645 | PPIL1 | HCC1_Meng | Human | Liver | HCC | 5.46e-62 | 2.58e-01 | 0.0246 |
51645 | PPIL1 | HCC2_Meng | Human | Liver | HCC | 3.20e-10 | 4.12e-02 | 0.0107 |
51645 | PPIL1 | HCC2 | Human | Liver | HCC | 3.17e-04 | 1.60e+00 | 0.5341 |
51645 | PPIL1 | Pt13.a | Human | Liver | HCC | 2.59e-06 | 2.58e-01 | 0.021 |
51645 | PPIL1 | Pt13.b | Human | Liver | HCC | 2.36e-18 | 3.16e-01 | 0.0251 |
51645 | PPIL1 | S014 | Human | Liver | HCC | 8.47e-15 | 4.55e-01 | 0.2254 |
51645 | PPIL1 | S015 | Human | Liver | HCC | 2.58e-27 | 8.48e-01 | 0.2375 |
51645 | PPIL1 | S016 | Human | Liver | HCC | 4.07e-20 | 6.33e-01 | 0.2243 |
51645 | PPIL1 | S027 | Human | Liver | HCC | 1.41e-05 | 4.67e-01 | 0.2446 |
51645 | PPIL1 | S028 | Human | Liver | HCC | 4.19e-13 | 5.65e-01 | 0.2503 |
51645 | PPIL1 | S029 | Human | Liver | HCC | 3.45e-15 | 6.03e-01 | 0.2581 |
51645 | PPIL1 | C04 | Human | Oral cavity | OSCC | 7.05e-28 | 1.29e+00 | 0.2633 |
51645 | PPIL1 | C21 | Human | Oral cavity | OSCC | 3.72e-56 | 1.85e+00 | 0.2678 |
51645 | PPIL1 | C30 | Human | Oral cavity | OSCC | 4.00e-44 | 1.86e+00 | 0.3055 |
51645 | PPIL1 | C38 | Human | Oral cavity | OSCC | 2.61e-05 | 6.16e-01 | 0.172 |
51645 | PPIL1 | C43 | Human | Oral cavity | OSCC | 2.65e-15 | 3.18e-01 | 0.1704 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
GO:0006457110 | Esophagus | ESCC | protein folding | 163/8552 | 212/18723 | 1.13e-20 | 1.74e-18 | 163 |
GO:001820816 | Esophagus | ESCC | peptidyl-proline modification | 46/8552 | 58/18723 | 1.59e-07 | 2.51e-06 | 46 |
GO:000041313 | Esophagus | ESCC | protein peptidyl-prolyl isomerization | 32/8552 | 42/18723 | 5.52e-05 | 4.27e-04 | 32 |
GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
GO:001820811 | Liver | HCC | peptidyl-proline modification | 42/7958 | 58/18723 | 3.73e-06 | 4.85e-05 | 42 |
GO:00004131 | Liver | HCC | protein peptidyl-prolyl isomerization | 31/7958 | 42/18723 | 3.83e-05 | 3.80e-04 | 31 |
GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
GO:000645718 | Oral cavity | OSCC | protein folding | 154/7305 | 212/18723 | 1.89e-23 | 4.60e-21 | 154 |
GO:00182088 | Oral cavity | OSCC | peptidyl-proline modification | 42/7305 | 58/18723 | 2.49e-07 | 3.92e-06 | 42 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPIL1 | SNV | Missense_Mutation | novel | c.208N>G | p.Thr70Ala | p.T70A | Q9Y3C6 | protein_coding | deleterious(0.02) | possibly_damaging(0.594) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
PPIL1 | SNV | Missense_Mutation | c.313N>T | p.Pro105Ser | p.P105S | Q9Y3C6 | protein_coding | deleterious(0.01) | possibly_damaging(0.682) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PPIL1 | SNV | Missense_Mutation | c.7N>A | p.Ala3Thr | p.A3T | Q9Y3C6 | protein_coding | tolerated_low_confidence(0.08) | benign(0) | TCGA-D5-6928-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
PPIL1 | SNV | Missense_Mutation | rs568130003 | c.349N>A | p.Ala117Thr | p.A117T | Q9Y3C6 | protein_coding | deleterious(0.04) | possibly_damaging(0.649) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PPIL1 | SNV | Missense_Mutation | novel | c.308N>T | p.Ala103Val | p.A103V | Q9Y3C6 | protein_coding | deleterious(0) | benign(0.39) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
PPIL1 | SNV | Missense_Mutation | novel | c.164N>T | p.Arg55Ile | p.R55I | Q9Y3C6 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
PPIL1 | SNV | Missense_Mutation | c.455G>A | p.Arg152His | p.R152H | Q9Y3C6 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PPIL1 | SNV | Missense_Mutation | c.7N>A | p.Ala3Thr | p.A3T | Q9Y3C6 | protein_coding | tolerated_low_confidence(0.08) | benign(0) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
PPIL1 | SNV | Missense_Mutation | c.455N>A | p.Arg152His | p.R152H | Q9Y3C6 | protein_coding | deleterious(0.01) | probably_damaging(0.936) | TCGA-EO-A22T-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PPIL1 | SNV | Missense_Mutation | novel | c.134N>A | p.Arg45Gln | p.R45Q | Q9Y3C6 | protein_coding | tolerated(0.06) | benign(0.1) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |